publication date: May. 5, 2017

Congress approves $2 billion increase for NIH in FY17 omnibus but FDA cancer center remains unfunded in legislative glitch

By Matthew Bin Han Ong

After seven months of continuing resolutions, Congress voted to pass a $1.1 trillion spending bill covering the remainder of the fiscal year 2017—approving a $2 billion increase for NIH.

The increase may signal the congressional reluctance to implement President Donald Trump’s scaled down vision for NIH, which would cut its budget by $5.8 billion in FY18 (The Cancer Letter, March 17).

By passing the omnibus spending bill, Congress has avoided a government shutdown.

In a development that may have an impact on oncology, the House narrowly passed a bill that replaces “Obamacare.” The measure, which is criticized by the mainstream oncology groups, now moves to the Senate.

The Senate approved the spending bill by a 79-18 vote May 4, a day after it passed the House by a 309-119 vote. The president is expected to sign the legislation.

In keeping with promises by members of Congress in FY16, the spending package provides $34.1 billion for NIH, a $2 billion increase that includes $352 million provided in the 21st Century Cures Act for targeted initiatives. NCI is slated to receive $5.7 billion, an increase of $475.8 … Continue reading Congress approves $2 billion increase for NIH in FY17 omnibus but FDA cancer center remains unfunded in legislative glitch

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.